Position in VTGN
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$9,685
-$1,529 QoQ
Shares Held
16,992
0.0% QoQ
Ownership
0.041%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in VTGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Truvestments Capital LLC holds $1,930,996 across 60 Biotechnology names. VTGN ranks #27 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
7,726 | $331,368 | |
| 2 | CRVS |
Corvus Pharmaceuticals, Inc.
|
10,257 | $150,059 | |
| 3 | CTMX |
CytomX Therapeutics, Inc.
|
27,428 | $128,911 | |
| 4 | PTGX |
Protagonist Therapeutics, Inc
|
1,161 | $122,369 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
3,680 | $101,936 | |
| 6 | KALV |
KalVista Pharmaceuticals, Inc.
|
4,684 | $94,288 | |
| 7 | BBIO |
BridgeBio Pharma, Inc.
|
1,155 | $85,770 | |
| 8 | DBVT |
DBV Technologies S.A.
|
3,892 | $81,303 |
All Filings in VTGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,685 | 16,992 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $11,214 | 16,992 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $30,725 | 8,655 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $14,310 | 7,155 | Shares | Sole | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||